Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

It gets tricky fast': benefits lawyer outlines legal pitfalls of HR offering – or not offering – weight loss drugs in Canada ...

“I’m making money to afford semagultide,” Rice, 42, who works three jobs to afford the expensive injectables, explained to her over 14,000 TikTok fans . Classified as a GLP-1, appetite-suppressing ...

If your constipation lasts for more than 3 days, speak with your doctor about options to help. You might need to add a stool ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer ...

ImmunoPrecise has outperformed the broader market in a spectacular fashion. As of now, IPA’s YTD performance stands at +81.64%, a staggering increase compared to the S&P 500’s YTD performance of just ...

Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings.

Oikos and its other popular brands are seeing a spike in demand as people taking the weight-loss medications turn to the portion-controlled snacks to meet their nutritional needs.

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

Fierce Healthcare is tracking workforce changes across healthcare in 2025. Stick with this tracker for the latest updates, ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...